Sara Kenkare-Mitra
Known title: President and Head of R&DCIK: 0001895592
Associated companies
Transaction History
| ALEC | ▼ Sell | Open Market | 41,687 | $47K | 12/3/2025 | View on chart |
| ALEC | ▼ Sell | Open Market | 23,638 | $59K | 9/2/2025 | View on chart |
| ALEC | ▲ Buy | Grant | 54,725 | $0 | 7/1/2025 | View on chart |
| ALEC | ▼ Sell | Open Market | 23,890 | $32K | 6/2/2025 | View on chart |
| ALEC | ▼ Sell | Open Market | 29,073 | $43K | 3/3/2025 | View on chart |
| ALEC | ▼ Sell | Open Market | 26,500 | $67K | 12/2/2024 | View on chart |
| ALEC | ▲ Buy | Grant | 300,000 | $0 | 10/1/2024 | View on chart |
| ALEC | ▼ Sell | Open Market | 13,926 | $68K | 9/3/2024 | View on chart |
| ALEC | ▼ Sell | Open Market | 13,206 | $63K | 6/3/2024 | View on chart |
| ALEC | ▼ Sell | Open Market | 10,169 | $70K | 3/4/2024 | View on chart |
| ALEC | ▼ Sell | Open Market | 12,519 | $70K | 12/4/2023 | View on chart |
| ALEC | ▲ Buy | Grant | 163,600 | $0 | 10/1/2023 | View on chart |
| ALEC | ▼ Sell | Open Market | 6,214 | $32K | 9/5/2023 | View on chart |
| ALEC | ▼ Sell | Open Market | 4,092 | $28K | 6/2/2023 | View on chart |
| ALEC | ▼ Sell | Open Market | 10,124 | $84K | 3/2/2023 | View on chart |
| ALEC | ▲ Buy | Grant | 80,365 | $0 | 10/1/2022 | View on chart |
| ALEC | ▲ Buy | Grant | 59,000 | $0 | 1/3/2022 | View on chart |
| ALEC | ▲ Buy | Grant | 59,000 | $0 | 1/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Alector (ALEC) sees purchases by NVIDIA and Merck
Recent filings show that NVIDIA and Merck have added positions in Alector. The involvement of these large technology and pharmaceutical firms may draw attention to the biotech company. The stock is currently trading near its 10‑touch support level of $1.47. Market participants may watch how this institutional interest aligns with the company's valuation.
Alector (ALEC) sees purchases by NVIDIA and Merck. Recent filings show that NVIDIA and Merck have added positions in Alector. The involvement of these large technology and pharmaceutical firms may draw attention to the biotech company. The stock is currently trading near its 10‑touch support level of $1.47. Market participants may watch how this institutional interest aligns with the company's valuation.